Yesterday’s FY2015 results from Cathay International showed a negative YoY performance, primarily as a result of the previously announced weak 2015 trading by its majority-owned and HK-listed subsidiary Lansen Pharma (which reported a 26% YoY EBIT decline in 2015, partially as a result of one-off factors). In addition, continued inositol pricing pressure negatively affected trading at (fully owned) Haizi. Prospects for 2016 include a return to growth at Lansen (mainly driven by new products) and ....
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
FY2015 results: affected by weak Lansen trading
- Published:
31 Mar 2016 -
Author:
Dr Jens Lindqvist -
Pages:
3
Yesterday’s FY2015 results from Cathay International showed a negative YoY performance, primarily as a result of the previously announced weak 2015 trading by its majority-owned and HK-listed subsidiary Lansen Pharma (which reported a 26% YoY EBIT decline in 2015, partially as a result of one-off factors). In addition, continued inositol pricing pressure negatively affected trading at (fully owned) Haizi. Prospects for 2016 include a return to growth at Lansen (mainly driven by new products) and ....